Today in Medicine

WEST PALM BEACH, FLORIDA, UNITED STATES, December 14, 2018 /EINPresswire.com/ — Known internationally for his lectures on aesthetics and his unparalleled patient results, Dr. Mark Pinsky is recognized as a world leader in plastic surgery. This claim is backed up by decades of research and practice as well as distinctions from top publications and respected boards of medicine.

Dr. Mark Pinsky has transformed the lives of his patients in the Palm Beach area for years, helping them to achieve lasting results through surgical and non-surgical procedures for their face and body. His offerings set him apart from the local competition, but he is recognized internationally as a driving force behind the regulation and enhancement of the aesthetics industry as a whole.

He graduated med school from Ohio State University and performed his general surgery residency with the University of Texas, Health Sciences of Houston. It was also with the University of Texas that he performed his plastic surgery residency and proved excellence in the aesthetics field. He was later certified by the American Board of Plastic Surgery and began meeting patient goals through various aesthetic procedures.

Dr. Mark A Pinsky has earned many distinctions that have helped him build one of the most successful practices in the entire country. He was voted the Best Plastic Surgeon in Palm Beach County and named one of Castle Connolly’s America’s Top Doctors. Beyond his local reach, readers may recognize his work in popular publications like Allure, New Beauty, Prevention, and In Touch magazine where he’s often profiled for his unique results. Dr. Pinsky has also appeared in the Aesthetic Plastic Surgery Journal where he shared his knowledge on advancing techniques in breast lifts.

His international fame is in thanks to his many guest lectures, appearing to speak throughout North America, China, and South Korea. Dr. Mark Pinsky is regularly invited to showcase work on nationally syndicated radio and TV stations and to share his expertise and opinions on the latest advances in plastic surgery with his peers. In this way, he not only teaches audiences about various procedures, but he also coaches his peers to adopt the most sophisticated practices and procedures available today.

Dr. Mark Pinsky has built an especially significant reputation for his outstanding work in the field of breast surgery. Not only a talented surgeon in the field, Dr. Pinsky is also a regular participant in revolutionary clinical studies focusing on various implants. His experience led to his appointment as an Investigator for the FDA clinical study of the Style 410 (gummy bear) implant. He is also one of only ten surgeons selected in the entire country to serve on Allergan’s Executive Council for Breast Aesthetics.

Dr. Mark Pinsky’s medical school distinctions, board certifications, and technical expertise set him far apart from the competition, but it’s his dedication to patient satisfaction that led his practice to success and acclaim far beyond the Palm Beach area.

Chris Hinman
Web Presence, LLC
+1 757-880-3579
email us here

Source: EIN Presswire

NEW YORK CITY, NEW YORK, USA, December 14, 2018 /EINPresswire.com/ — Dov Bechhofer is a computer engineer exploring how technology shapes our present and what technological advancements we can expect in the future. Recently, the FDA Commissioner announced the administration would increase its focus on digital services moving forward, which means new potentials for doctors and patients alike.

In order for doctors to unveil new treatments and for patients to have a richer variety of procedural options, they have to first be evaluated for safety by the Food and Drug Administration (FDA). Patients and doctors are dependent on the administration’s approval, so it’s refreshing to hear that the FDA is taking steps towards digital health contributions that will provide more sophisticated and state-of-the-art services.

Computer Engineer Dov Bechhofer keeps a close eye on emerging tech and he’s confident that the FDA’s decision to explore more digital health resources is something that can and will benefit everyone.

“We live in the future,” Dov Bechhofer says. “We have smart cars, smartphones, smart homes, and now smart cities on the rise. Smart hospitals were bound to come down the line.”

Advances in medical technology and treatments bring faster, more effective results to patients. Digital health also encompasses communication between doctors and patients, and can help to prioritize care for optimal service. Better tracking of patient conditions will make diagnosing and treating ailments easier and will require less dedicated time from busy physicians.

Soon, prescriptions may be filled through a smartphone app instead of patients having to go into a clinic to get checked out. Patients and consumers will be able to use digital health to better manage and track their health far more accurately than they can currently with wearable tech like Fitbits and iWatches.

Apart from that, the FDA is looking into advancements that will hopefully reduce inefficiencies, improve access, enhance quality, reduce costs, and make medicine and treatments more personalized for patients. Current devices will be updated to add digital features and new systems of categorization and storing medical data will be implemented.

“There’s a lot of money going into tech development,” says Dov Bechhofer. “Our devices are updating faster than ever with new capabilities and faster, more complex forms of data transfer unrolled each year. The medical industry can take advantage of this.”

The FDA will advance digital health through an official Digital Health Program that seeks to “better protect and promote public health and provide continued regulatory clarity.” It aims to accomplish this by encouraging collaborations and improving outreach to digital health customers. In addition, they will develop and implement regulatory strategies and policies for new digital health technologies.

The subject of digital health gains momentum as corporations and some of the world’s largest developers create new paths to the market. Some of the topics currently under discussion are wireless medical devices, mobile medical apps, telemedicine, new data systems, cybersecurity and more. With tech focus moving to more advanced machines and powerful systems, the FDA’s actions will be instrumental to the limits and potential of the future’s digital health.

Chris Hinman
Web Presence, LLC
+1 7578803579
email us here

Source: EIN Presswire

Physician Dr. David Anthony Miranda looks at plans for new medical schools at the University of Houston and throughout Texas.

WEST LAKE HILLS, TEXAS, UNITED STATES, December 14, 2018 /EINPresswire.com/ — As a series of developments continue to move from early planning through to final approval, construction has already begun on a number of new medical schools and teaching facilities in the state of Texas, Dr. David Anthony Miranda reveals. Plans to establish a medical school at the University of Houston have recently been approved by the Texas Higher Education Coordinating Board, with the facility due to open its doors in mid-late 2020, according to the physician.

"The University of Houston College of Medicine," Dr. Miranda explains, "plans to focus predominantly on training primary care physicians so that they may practice in medically under served communities."

According to the doctor, the Association of American Medical Colleges has ranked Texas 47th out of the 50 U.S. states regarding adequate physician coverage, with primary care physician roles in the state often challenging to fill, particularly in more rural settings which lack specialty medical backup.

An expert in the field and now based in San Antonio, Texas, Dr. Miranda has spent three decades driven by a passion for caring for medically under served, predominantly rural populations, traveling tens of thousands of miles across the United States in the process of caring for those in need.

"The University of Houston College of Medicine has received an endorsement from the Texas Higher Education Coordinating Board affording them an indication that they're right on schedule," explains Dr. Miranda of the university's efforts to begin teaching medical students by the end of 2020, having already raised over $35 million in funds through private philanthropy for the medical college. The total project cost is currently expected to reach in excess of $450 million.

Alongside the University of Houston, and further slated to be operational by late 2020, Sam Houston State University, too, also plans to have established its own medical school within two years, according to Dr. Miranda. Already, he goes on to point out, the new Dell Medical School at the University of Texas at Austin is open, as is the new University of Texas Rio Grande School of Medicine in Edinburg, in addition to the new University of the Incarnate School of Osteopathic Medicine in San Antonio.

"Already well beyond planning and approval, there's also the Texas Christian University," adds Dr. Miranda, wrapping up, "and the University of North Texas Health Science Center in Fort Worth which have joined forces, each intending to begin teaching medicine in 2019."

Dr. David Anthony Miranda is a partner of Fit-Life MD, a physician-owned medical wellness and fitness clinic in San Antonio, Texas. The mission of Fit-Life MD is to improve the overall health and wellness of patients through individually designed and personalized treatment plans tailored toward general health and physical well-being. Dr. Miranda's personal interests include investing in the stock market, especially publicly-traded healthcare stocks, as well as music, theater, and film.

Chris Hinman
email us here
Web Presence, LLC
+1 7578803579

Source: EIN Presswire

Industry best noise cancelling, speech recognition microphone

Accurately document patient information without being overheard by others while additionally eliminating all background noise.

SEATTLE, WASHINGTON, USA, December 14, 2018 /EINPresswire.com/ — Voice technology in healthcare is not yet the ubiquitous application that we believe it will soon become. The major concerns are patient privacy, HIPAA compliance, potentially leaving confidential information unprotected and the challenge of clear voice communication in a noisy and busy clinical setting, particularly when complex medical vocabulary is required.

Many physicians use voice technology for clinical decision support and documentation in their office or home however they are much less inclined to do so in the presence of their patients.
There is a practical and affordable solution to this problem.

Talk Technologies engineers and manufactures specialized microphones (stenomasks) that allow clinicians to use speech recognition and verbally communicate in public without anyone overhearing them. Our voice isolating technology enables private transcription and verbal communication while simultaneously eliminating all background noise.

Stenomask functions like a sound-booth only in pocket sized form, guaranteeing clear voice communications in loud and busy clinical settings. Your documentation can now be captured anywhere in complete privacy.

Advantages:

Complies with HIPAA privacy and security rules
Decreases potential security risks and protects the privacy of individuals’ health information
Lightweight, affordable and road worthy durability
Compatible with all speech recognition software including Dragon medical
No start up time or learning curve, simply plug in and go
Doctors that use clinical speech recognition are 23% happier
They feel more confident about technology and have a better experience
They move freely, spend more time with patients and can go home on time

Privately transcribing anywhere is an antidote to burnout. It helps doctors feel better about documentation, more satisfied and freer to practice as they see fit.

For more information please email dwebb@talktech.com or visit our website talktech.com

D Webb
Talk Technologies
888 811 9944
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Stenomask SR Pro-1- silently transcribing with Dragon 15

Source: EIN Presswire

SMi Group’s next annual Adaptive Designs in Clinical Trials conference is thrilled to welcome Sandeep Menon, Pfizer Inc.

LONDON, UNITED KINGDOM, December 14, 2018 /EINPresswire.com/ — SMi Group’s next annual Adaptive Designs in Clinical Trials conference is thrilled to welcome Sandeep Menon, Vice President and Head of Early Clinical Development at Pfizer Inc. onto the speaker panel for 2019.

He is currently leading a multi- functional global team which includes Biostatisticians, Clinical Pharmacologists, Clinicians, Precision Medicine Scientists and Digital Medicine Scientists. Sandeep has extensive experience in late phase studies and with regulatory interactions especially with the FDA (US Agency), EMA (European Agency) and PMDA (Japan Agency). He is internationally known for his technical expertise especially in the area of adaptive designs, personalized medicine, multi-regional trials, and small populations and has participated in the core review of draft version of the regulatory guidance documents.

A key topic focus in Sandeep’s presentation is statistical and design considerations in personalised medicine. He will be discussing Identifying genetic, genomic and clinical characteristics to predict patient susceptibility. Biomarkers and the challenges in their use for diagnostics and looking into selecting appropriate designs to determine biomarker performance, reliability and regulatory acceptance.

Additionally, the vice president will explore case studies for biomarker driven trials.

For those looking to attend there is currently a £200 early-bird saving.

Further information is available at: www.adaptivedesigns.co.uk/einpr2

SMi Presents the 11th Annual Conference on…
Adaptive Designs in Clinical Trials
Date: 1-2 April 2019
Location: London, UK
Website: www.adaptivedesigns.co.uk/einpr2

—ENDS—

Contact Information:

For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+1 2078276088
email us here

Source: EIN Presswire

Energy Efficient Passive Inspired Design.

Open floor plan – Living Room

Custom cabinet with Induction BOSCH range.

CA Building Code adopts Net-Zero Energy by 20/20. Explore this Energy Efficient home and save hundreds per month now by combining rooftop solar and Heat Pump.

SAN JOSE, CALIFORNIA, USA, December 14, 2018 /EINPresswire.com/ — Invest in SIDCO – (Sustainable Innovative Design & Construction) home and enjoy the comfortable environment and best indoor air quality in a Energy Efficient Home. Net Zero Home produces more energy than it consumes over a period of one year. Homes uses renewable energy produced by Solar panels which are prepaid and are included in price the house with a 25 year warranty. SIDCO Homes may provide allowance for the lease of an electric car of your choice thus taking one more car off the road that uses combustion fuel. But why do all this – Visit this home at 4910 Kenlar Drive, San Jose, Ca. 95124 or contact Francine Terrell at 408-202-5875 for personal viewing. Here is the rest of the story.

Mohan Mahal – Founder & CEO of SIDCO Homes is "Thankful to the Donor for a Gift of Life." for receiving a Heart Transplant 25 years ago. Till today I do not know if I got inspired or my new Heart that gave me new life got inspired by Dr Wolfgang Feist in Germany to build Passive Homes. A passive home is a rigorous, voluntary standard for energy efficiency in a building’s ecological footprint. It results in ultra low-energy buildings that require little energy for space heating and cooling. Passive Houses allow for space heating and cooling related energy savings of up to 90% compared with typical building it makes efficient use of the sun, internal heat sources and heat recovery, rendering conventional heating systems unnecessary throughout even in the coldest of winters.

How do we achieve these results in a remodeling project.

1. Make sure your walls and attic are well insulated.: – The house was taken down to the stud level and framers installed new walls where needed. Title 24 modeling was done to make the attic space as the closed sealed attic. Closed cell spray foam was used to seal the walls and the under the roof. This provided insulation and sealed all the openings to make the house airtight and Energy Efficient.

2.Upgrade or replace windows: – We replaced and installed all new double pane windows with the low u value. to keep the inside worm during winter and cool during summer months. The windows are sealed and made air tight.

3. Replace an older furnace with a high-efficiency system: – This is the most significant part of the Net Zero Home to conserve the energy. Typical homes have the furnaces using the gas for heating and air conditioning for cooling. SIDCO now has moved on to the Heat Pump technology which is more efficient than the furnaces. It provide the heating and cooling for the property. The power for these units are provided by Solar PV's.

4. Improve the efficiency of your hot water system: – The conventional systems have been water heaters keeping the water hot at all times. We have converted this house to the Tankless water system with a recirculation pump with enough capacity to supply the home with three bathrooms and a kitchen. There is new copper plumbing in the house and all the drain lines have also been replaced and installed.

5. Replace incandescent lightbulbs with LED lights: – This house has 100% LED lights in all the rooms. We have also use motion sensors in the bathrooms as needed by code to conserve the energy. In addition to this we have all new electric wiring in the whole house.

6. Install new refrigerator and appliances: – To improve the quality of the air in the house we have used BOSCH new appliances. The stove is induction cooking range which uses energy only when the pot is placed on the stove. To maximize the use of the Solar PV power the Washer and Dryer for this house is Miele Electric.

7. Installation of the new Roof:- The house has a complete new roof with 50 year warranty of Presidential Elite roofing material with OSB underlayment.

8. Totally Landscaped with water conservation drip system: – A project tis not complete till you give it a good curve appeal. We have the property completely landscaped for the family with water conservation plant and drip system for irrigation. There is a complete walk way around the house with concrete patio and storage area.

9. Schedule an energy audit: – Once the house was built and the doors and windows installed we got the blower door test done and applied for the US Departments's Home Energy Report. Once we got the result we were very proud of our accomplishment of building a home that got the highest score of 10 out of 10.

Where does the saving come from when you invest in a SIDCO Home? A typical homeowner with four bedrooms and 2.5 baths and four occupants spends on an average $200 on the energy bill about $200 for driving a gas car and another $200 on the payment or lease of car.

SIDCO – Homes are built with: – Solar panels installed and paid for with a 25-year warranty with electric bill less than $50.00. SIDCO may provide the allowance to pay for a two years lease on an electric car and the house has a 240 volt 40 Amp outlet installed for charging thus a saving of hundreds per month.

Please help us mitigate the climate change one house at a time and invest in the SIDCO Homes and enjoy the comfort of a Passive Inspired Energy Efficient Home.

Mohan Mahal
SIDCO Homes Inc
+1 408-314-3454
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This is Energy Efficient home with indoor air quality index of less than 50 during the Paradise fire.

Source: EIN Presswire

RNA Therapeutics 2019

Chief Scientific Officer of MiNA Therapeutics set to speak at RNA Therapeutics 2019, following MiNA Therapeutics’ successful liver cancer therapy news.

LONDON, LONDON, UNITED KINGDOM, December 14, 2018 /EINPresswire.com/ — The field of RNA therapeutics has seen rapid development as RNA drugs are now being utilised for personalised medicines and immunotherapy, and to address genetic, infectious and chronic diseases.

Next year's 10th annual conference on RNA Therapeutics, taking place in London on 20th – 21st February 2019, is set to address the latest advancements and challenges in the industry as a host of scientific pioneers and senior experts gather in London to share their extensive knowledge and expertise in the field.

In recent news, pioneer in RNA activation therapeutics MiNA Therapeutics recently announced their positive findings from MTL-CEBPA clinical trial in patients with advanced liver cancer.

The British biotech reported observations of tumour responses in patients when administered liver cancer therapies after treatment with MTL-CEBPA, even reporting complete responses in two patients, supporting evidence that RNA treatment can enhance liver cancer patients’ response to standard cancer therapies.*

The encouraging results of the trial are one of the many developments contributing to the exciting advances in RNA therapy, as after a long time in development, RNA therapies are finally beginning to enter the market.

MiNA Therapeutics' Chief Scientific Officer, David Blakey, is set to give a keynote presentation at next year's RNA Therapeutics conference in London, where he will discuss "Small Activating RNA – From bench to bedside" and expand on the clinical trial, as well as explore in detail novel MOA of small activating RNAs to upregulate gene expression, preclinical studies demonstrating MOA and therapeutic activity, and clinical experience with MTL-CEBPA – the first saRNA in the clinic.

Delegates will also have the opportunity of hearing from the CEO of biotech Exicure; David Giljohann, who will be speaking about the therapeutic applications of spherical nucleic acids (SNAs) "Spherical Nucleic Acids: Clinical Progress".

David will be concentrating on how localization to endosome permits large numbers of SNA’s to be delivered with low toxicity, how SNAs can be used to knockdown genes or interest, or activate immune pathways productively, as well as AST-008 TLR9 agonist clinical trial progress, and XCUR-17 topical antisense in psoriasis.

Attendees will have the chance to explore the advantages of delivery via SNAs, a nano particle-based therapeutic with benefits including entry independent of transfection agents, resistance to degradation, and ability to cross biological barriers.

In addition, with 7+ hours of networking included, there will be multiple opportunities for participants to interact with key industry leaders, including Sanofi, Exicure, Roche, MHRA, The RNA Institute, GSK, AstraZeneca, ProQR, and many more.

The event brochure containing the full agenda and speaker line-up, as well as other exclusive content is available to download on the website: http://www.therapeutics-rna.com/einpr

10th RNA Therapeutics Conference
20th – 21st February 2019
London, UK

*Labiotech.eu

—END—

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
+442078276124
email us here

Source: EIN Presswire

K Todd Wallace, Wallace Meyaski Law Firm

K Todd Wallace, Wallace Meyaski Law Firm, conference room

K. Todd Wallace, Attorney in New Orleans, Louisiana

Todd Wallace, Attorney of the Month, Attorney at Law Magazine 2013

Website of Law Firm Wallace Meyaski, K. Todd Wallace

At issue in the case was Atrium Health’s use of anti-steering provision in its contracts with health insurance companies, comments K Todd Wallace.

Wallace Meyaski Law Firm (N/A:N/A)

NEW ORLEANS, LOUISIANA, UNITED STATES, December 14, 2018 /EINPresswire.com/ — New Orleans attorney K. Todd Wallace published a comment on the recent U.S. Department of Justice settlement with Atrium Health. The settlement was announced by the Justice Department when submitting the proposed settlement for court approval in a case that has been ongoing since 2016. At issue in the case was Atrium Health’s use of anti-steering provision in its contracts with health insurance companies. As explained by the DOJ in its press release announcing the settlement, “[t]he Department alleged that Atrium, the dominant hospital system in the Charlotte area, used its market power to restrict health insurers from encouraging consumers to choose healthcare providers that offer better overall value. The restrictions also constrained insurers from providing consumers and employers with information regarding the cost and quality of alternative health benefit plans.” If approved, the settlement would enjoin Atrium Health from seeking to enforce the anti-steering provision against health insurers and also prohibit including such provision in its contract with insurers in the future.

Mr. Wallace notes that the settlement represents an interesting development in light of the recent U.S. Supreme Court decision in Ohio v. American Express. In the American Express case, the Supreme Court held that anti-steering provision in a two sided-market must be evaluated as a whole. Many legal scholars saw this development as potentially having significant effect on the analysis of how other multiparty-market antitrust cases would be evaluated, such as those involving the health insurance industry.

Interestingly, the Second Circuit’s decision in the American Express case, which applied the same reasoning later upheld by the Supreme Court, was the basis for Atrium Health’s supplemental arguments in its 12(c) Motion for Judgment on the Pleadings. In their opposition, the DOJ argued that American Express was wrongly decided by the Second Circuit, a position that would ultimately be rejected by the Supreme Court. But more importantly, the DOJ argued that the anti-steering provision at issue harms both the patients and insurers. The DOJ argued in their opposition briefing that “Plaintiffs also have alleged actual anticompetitive effects on price and output for patients and the insurers who pay for their health care. In Paragraph 14 of the Complaint, Plaintiffs allege that when insurers have steered in spite of CHS’s restrictions, consumers have paid less for health care. And in Paragraph 27 of the Complaint, Plaintiffs allege that ‘[a]s a result of this reduced competition due to CHS’s steering restrictions, individuals and employers in the Charlotte area pay higher prices’ and have less product choice. These are allegations of actual ongoing harm: CHS’s steering restrictions result in Charlotte consumers paying more for health care.”

It appears that the DOJ satisfied the whole market approach as required by American Express, at least at the initial pleading stage. Although one can only speculate as to what ultimately motivated the parties to settle, it would be reasonable to assume that the dual harm alleged by the DOJ could have played a factor the decision rather than pursue its 12(c) motion to the end.

About K Todd Wallace

Kenneth Todd Wallace is an attorney and founding partner of the law firm Wallace Meyaski LLC in New Orleans, Louisiana. He has nearly 20 years of experience in the legal and business professions with established excellence in trial advocacy, negotiation, strategic and initiative planning, employment law compliance, government relations, mergers and acquisitions, and team building.

Blog at: https://ktoddwallaceblog.blogspot.com/
News: https://hype.news/k-todd-wallace-attorney-in-new-orleans-louisiana-usa/
News: https://attorneygazette.com/kenneth-todd-wallace
Law Firm Website: http://www.walmey.com/our-attorneys/k-todd-wallace/
Facebook page of the Law Firm: https://www.facebook.com/WallaceMeyaski/
Facebook page of Kenneth Todd Wallace:
https://www.facebook.com/kennethtodd.wallace.3
LinkedIn Profile of Kenneth Todd Wallace: https://www.linkedin.com/in/k-todd-wallace-03895358/
Lawyer Profile at: http://lawyers.lawyerlegion.com/louisiana/kenneth-todd-wallace-18001529
Attorney Profile: https://www.lawyers.com/new-orleans/louisiana/kenneth-todd-wallace-604175-a/

K. Todd Wallace, Attorney at Law
Wallace Meyaski Law Firm
+1 504-644-2011
email us here
Visit us on social media:
Facebook
LinkedIn

WSOCTV9: Atrium Health, NC Attorney General Settle Antitrust Lawsuit Over Health Care Costs

Source: EIN Presswire

Dr. Greg Vigna

We provide ‘Sanchez Proof’ testimony from physician experts in fields including orthopedic, spinal, pain management, brain injury, and now burn management.

SANTA BARBARA, CALIFORNIA, UNITED STATES, December 14, 2018 /EINPresswire.com/ — Academic Physician Life Care Planning, LLC provides Sanchez proof testimony for its defense and plaintiff life care plans for catastrophic burn care from Board Certified physicians in Plastic Surgery and Surgical Critical Care.

Historically, evidence that was presented to the jury that relates to the cost of future medical care for an injured person was provided by costing research obtained by a variety of sources including the CPT Codes and data obtained by phone calls to vendors of the actual cost charged for goods and services in the location where the injured person resides. In California, the Sanchez Decision in June of 2016 preclude this evidence as ‘hearsay’.

Academic Physician Life Care Planning, LLC, led by Dr. Greg Vigna provides ‘Sanchez Proof’ testimony as its physician experts base their opinion on ‘knowledge, skill, experience, education, and training’ obtained over decades of patient management in the field of orthopedic trauma, spinal cord injury, interventional pain management, and traumatic brain injury. Now Academic Physician Life Care Planning, LLC provides expert life care planning services with burn experts.

Dr. Greg Vigna, a physician, lawyer, and life care planner explains, “Catastrophic burn care is a specialty that requires unique skills, specialization, experience and is practiced by few plastic surgeons and general surgeons across the country. Our life care plans will include an academically based Board Certified Plastic Surgeon who practices daily in a major burn center which allows for him to be qualified as an expert and provide demonstrative and testimonial evidence for catastrophic burns.”

Academic Physician Life Care Planning, LLC provides Life Care Plans, with physicians from multiple specialties for no additional cost for its defense and plaintiff life care plans. Academic Physician Life Care Planning, LLC physician experts are prepared to testify to the cost of future care and the appropriateness of all medical and non-medical care provided for in its life care plan at no extra cost to its clients.

Greg Vigna
Greg Vigna, M.D., J.D.
1-800-761-9206
email us here

Source: EIN Presswire

CVR Medical Corp. (OTCQB:CRRVF)

DENVER, NC, USA, December 13, 2018 /EINPresswire.com/ —

CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector announces that its patented, disruptive Carotid Stenotic Scan (CSS) has passed the IEC 60601-1-2 edition 4, General Requirements for Basic Safety and Essential Performance – Electromagnetic Disturbances conducted by TUV Rheinland of North America. TUV Rheinland of North America, is one of the leading providers of product safety certifications worldwide, covering an assortment of items such as medical devices, home appliances, audio/video products, medical products, textiles and telecommunication equipment. This testing is required for the CSS’s subsequent De Novo submission to the FDA for US market clearance and will show that the device is compliant with all IEC 60601-1-2 EMC requirements. The International Electrotechnical Commission (IEC), based in Geneva, Switzerland, publishes the 60601 series of technical standards that allow medical device developers to demonstrate the safety and essential performance of their medical equipment. Upon completion of EMC testing, TUV North America started IEC 60601-1 safety testing which includes, software and hardware validation , fire and electrical safety and mechanical failure. As announced, CVR’s previous guidance relating to FDA submission remains unchanged for Q1 2019.

In speaking to CVR’s VP of Program Management & Product Development, Lewis Crenshaw, the TUV engineer stated “CVR’s team did a tremendous job preparing documentation and hardware for IEC 60601-1-2 EMC safety testing. This allowed the TUV team to quickly and efficiently tackle the testing, review technical documents and draft and sign the EMC test report during the busiest time of our year.”

Tony Robinson, CVR Medical’s Chief Operating Officer stated, “This represents one of the final hurdles standing between CVR and the FDA submission that we have been working so diligently towards. Many companies are significantly delayed by requirements such as EMC, but thanks to the thoroughness of the CVR engineering team and open dialogue which TUV provided, we have been able to maintain our momentum toward our objectives. Working with TUV has been the epitome of efficiency and effectiveness, even during this extraordinarily busy time. We know that when our CSS device is placed into the clinical setting we are holding ourselves to the industry’s highest standard of electrical safety.”

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan (CSS). The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in pivotal clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Chairman

For further information contact:
Peter Bakema, CEO, President and Chairman
Email: info@cvrmed.com
or
Marc S. Lubow.
Vice President Capital Markets, Director Investor Relations
904-923-4037
marclubow@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Marc Lubow
CVR Medical Corp.
+1 904-923-4037
email us here

Source: EIN Presswire